| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5834422 | NOVO NORDISK INC | AspB28 insulin compositions |
Sep, 2013
(10 years ago) | |
| US5547930 | NOVO NORDISK INC | AspB28 insulin crystals |
Sep, 2013
(10 years ago) | |
| US5840680 | NOVO NORDISK INC | ASPB28 insulin crystals |
Sep, 2013
(10 years ago) | |
| US5618913 | NOVO NORDISK INC | Insulin analogues |
Jun, 2014
(9 years ago) | |
|
US5618913 (Pediatric) | NOVO NORDISK INC | Insulin analogues |
Dec, 2014
(9 years ago) | |
| US5866538 | NOVO NORDISK INC | Insulin preparations containing NaCl |
Jun, 2017
(6 years ago) | |
|
US5866538 (Pediatric) | NOVO NORDISK INC | Insulin preparations containing NaCl |
Dec, 2017
(6 years ago) | |
| US6004297 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(5 years ago) | |
| USRE43834 | NOVO NORDISK INC | Injection syringe |
Jan, 2019
(5 years ago) | |
| USRE41956 | NOVO NORDISK INC | Dose setting limiter |
Jan, 2021
(3 years ago) | |
| US8579869 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(10 months ago) | |
| US7762994 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(14 days from now) | |
| US9265893 | NOVO NORDISK INC | Injection button |
Sep, 2032
(8 years from now) | |
Novolog Mix 70/30 Flexpen is owned by Novo Nordisk Inc.
Novolog Mix 70/30 Flexpen contains Insulin Aspart Protamine Recombinant; Insulin Aspart Recombinant.
Novolog Mix 70/30 Flexpen has a total of 13 drug patents out of which 11 drug patents have expired.
Expired drug patents of Novolog Mix 70/30 Flexpen are:
- US5834422
- US5547930
- US5840680
- US5618913
- US5618913*PED
- US5866538
- US5866538*PED
- US6004297
- USRE43834
- USRE41956
- US8579869
Novolog Mix 70/30 Flexpen was authorised for market use on 01 November, 2001.
Novolog Mix 70/30 Flexpen is available in injectable;subcutaneous dosage forms.
Novolog Mix 70/30 Flexpen can be used as method of treating a patient suffering from diabetes mellitus.
The generics of Novolog Mix 70/30 Flexpen are possible to be released after 23 September, 2032.
Market Authorisation Date: 01 November, 2001
Treatment: Method of treating a patient suffering from diabetes mellitus
Dosage: INJECTABLE;SUBCUTANEOUS
NOVOLOG MIX 70/30 FLEXPEN family patents
